PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease
Open Access
- 23 April 2020
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
Abstract
Acute graft-versus-host disease (aGVHD) is a T cell-mediated immunological disorder and the leading cause of nonrelapse mortality in patients who receive allogeneic hematopoietic cell transplants. Based on recent observations that protein arginine met hyltransferase 5 (PRMT5) and arginine methylation are upregulated in activated memory T cells, we hypothesized that PRMT5 is involved in the pathogenesis of aGVHD. Here, we show that PRMT5 expression and enzymatic activity were upregulated in activated T cells in vitro and in T cells from mice developing aGVHD after allogeneic transplant. PRMT5 expression was also upregulated in T cells of patients who developed aGVHD after allogeneic hematopoietic cell transplant compared with those who did not develop aGVHD. PRMT5 inhibition using a selective small-molecule inhibitor (C220) substantially reduced mouse and human allogeneic T cell proliferation and inflammatory IFN-gamma and IL-17 cytokine production. Administration of PRMTS small-molecule inhibitors substantially improves survival, reducing disease incidence and clinical severity in mouse models of aGVHD without adversely affecting engraftment. Importantly, we show that PRMT5 inhibition retained the beneficial graft-versus-leukemia effect by maintaining cytotoxic CD8(+) T cell responses. Mechanistically, we show that PRMT5 inhibition potently reduced STAT1 phosphorylation as well as transcription of proinflammatory genes, including interferon-stimulated genes and IL-17. Additionally, PRMT5 inhibition deregulates the cell cycle in activated T cells and disrupts signaling by affecting ERK1/2 phosphorylation. Thus, we have identified PRMT5 as a regulator of T cell responses and as a therapeutic target in aGVHD.Funding Information
- Leukemia Research Foundation (GRT00046936)
- NIH Office of the Director (P30 CA016058)
- National Cancer Institute (2K12 CA133250-11)
- The Ohio State University (Pelotonia Junior Faculty Award)
- N/A (N/A)
This publication has 98 references indexed in Scilit:
- PRMT5 dimethylates R30 of the p65 subunit to activate NF-κBProceedings of the National Academy of Sciences of the United States of America, 2013
- Arginine methylation controls growth regulation by E2F-1The EMBO Journal, 2012
- Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variationNucleic Acids Research, 2012
- Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic ContinuumScience, 2011
- Dichotomous Role of Interferon-γ in Allogeneic Bone Marrow TransplantTransplantation and Cellular Therapy, 2009
- Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune DiseasesImmunity, 2009
- PRMT5 is required for cell-cycle progression and p53 tumor suppressor functionNucleic Acids Research, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- Protein Arginine Methylation in Mammals: Who, What, and WhyMolecular Cell, 2009
- The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transitionOncogene, 2007